Dbv Technologies הון עצמי 2024

מה עושה Dbv Technologies?

DBV Technologies SA (DBV) is a biopharmaceutical company specializing in the development of therapies for allergic diseases. The company was founded in 2002 by Pierre-Henri Benhamou in France. Its objective is to set new standards in the treatment of allergies through innovative approaches. DBV's business model is based on the research and development of products based on epicutaneous tests (application of allergens on the skin). This alternative method to the common oral immunotherapy (OIT) treats allergic reactions using special patch products. These patches contain the allergens that trigger an allergic reaction in the patient. Through continuous contact with the allergens, the body's defense mechanisms learn that there is no threat and suppress the allergic reaction. DBV offers two products based on epicutaneous tests: Viaskin Peanut and Viaskin Milk. Viaskin Peanut is DBV's first product for the treatment of peanut allergies, while Viaskin Milk is the next product in the pipeline. Viaskin Peanut is a patch that contains a microdose of peanut protein. It is applied to the patient's skin, gradually familiarizing the immune system with the allergen and reducing allergic reactions. The patch can also be used in children, making it an important innovation in the treatment of peanut allergies. Viaskin Milk is also a patch that contains specific proteins found in milk. This patch aims to revolutionize the treatment of milk intolerances, as there are currently no specific therapies for this type of allergy. Again, this is an epicutaneous test. DBV has previously entered into several partnerships with other companies. This includes a collaboration with Nestle to further expand the potential of epicutaneous test products. Networking with insurers and health insurance companies is also an important strategic step in establishing the use of epicutaneous test products in practice. The company is particularly active in Europe and the USA. Its IPO took place in 2012. In 2017, DBV became the first French drug manufacturer to receive approval from the European Medicines Agency (EMA) for Viaskin Peanut. DBV Technologies SA has great potential in the development of epicutaneous products for long-term treatment of allergies. The company has achieved promising results in a short period of time and has established itself as an innovative player in the field of allergology. Dbv Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.